Showing 1 - 20 results of 24 for search '(( 50 mg decrease ) OR ( 10 ((greater decrease) OR (((a decrease) OR (mean decrease)))) ))~', query time: 1.01s Refine Results
  1. 1

    Supplementary Material for: Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland by Haase C.L. (11305977)

    Published 2021
    “…<b><i>Introduction:</i></b> Data from randomized controlled trials show that liraglutide 3.0 mg, in combination with diet and exercise, is associated with greater weight loss than diet and exercise alone in patients with obesity. …”
  2. 2
  3. 3
  4. 4

    Table1_Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model.DOC by Victor Sokolov (14181554)

    Published 2023
    “…Finally, the efficacy of 5 and 10-mg doses, represented by the mean HbA1c reduction at week 24 of dapagliflozin treatment, was shown to be notably greater than the 1- and 2.5-mg doses.…”
  5. 5
  6. 6
  7. 7

    B12A-05: A review and synthesis of nitrogen inputs, outputs and dynamics to support the implementation of nitrogen cap reduction in the Lake Rotorua catchment. by Troy Baisden (11213706)

    Published 2022
    “…<p>American Geophysical Union Fall Meeting Washington DC 10-14 December 2018 2018</p> <p><a href="https://agu.confex.com/agu/fm18/meetingapp.cgi/Paper/453327" target="_blank">https://agu.confex.com/agu/fm18/meetingapp.cgi/Paper/453327</a></p> <p>Nitrogen (N) budgets and dynamics in Rotorua, a 80 km2 lake with a 500 km2 catchment, have been the subject of intensive research for 50 years, and have also been the focus of large-scale restoration interventions involving both policy and management. …”
  8. 8
  9. 9
  10. 10
  11. 11

    DataSheet_1_A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor ac... by Zhiyu Huang (638377)

    Published 2023
    “…In the dose-escalation phase, patients were treated with QL1604 at 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg intravenously once every 2 weeks (Q2W) in an accelerated titration with a traditional 3 + 3 design, followed by a dose-expansion phase at 3 mg/kg Q2W, 3 mg/kg once every 3 weeks (Q3W), 10 mg/kg Q2W and a fixed dose of 200 mg Q3W. …”
  12. 12
  13. 13
  14. 14
  15. 15

    Antihypertensive effect and the underlying mechanisms of action of phytolaccagenin in rat models by Imran Ul Haq (12676309)

    Published 2022
    “…However, Nω-nitro-L-arginine methyl ester (L-NAME) (100 mg/kg) pretreatment modified the effect of phytolaccagenin on blood pressure with greater response. …”
  16. 16

    Supplementary Material for: Urea Reduction in Acute Kidney Injury and Mortality Risk by Chávez-Íñiguez J.S. (11189730)

    Published 2023
    “…We create 4 groups of urea reduction ratio (UXR) stratified by their decrease in urea from the highest index value in comparison to the value on day 10 (0%, 1–25%, 26–50%, and >50%), or at the time of death or discharge if prior to 10 days. …”
  17. 17

    Adhesion of Als5 to collagen type IV involves recognition of carbohydrate residues on collagen type IV but is not solely determined by it. by Mohammad Faiz Ahmad (172608)

    Published 2012
    “…Flow chart representing the various steps of the assay is shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0035305#pone.0035305.s005" target="_blank">Figure S5</a>.…”
  18. 18

    Supplementary Material for: Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial by Lam D. (11931392)

    Published 2022
    “…During a mean follow-up of 5.6 years, 131 participants (9.9%) experienced the composite kidney outcome. …”
  19. 19
  20. 20

    Locomotor response to CNO under normal conditions. by Hailong Li (216327)

    Published 2019
    “…<p><b>A)</b> Four animals that had received viral infusions and nine that received sham surgeries were exposed to various doses of CNO (0, 0.15, 0.3, 0.6, or 1.0 mg/kg) across 5 days under normal/no novelty present conditions. …”